Key facts
- It has raised $2.0M across 1 recorded rounds; the latest was Seed Round ($2.0M) in Oct 2024.
- EyeMacular Regeneration has filed 2 Form Ds with the SEC since 2024, most recently Oct 2025 ($2.0M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for EyeMacular Regeneration
Funding rounds
1 roundsAbout EyeMacular Regeneration
Developer of novel therapies for advanced retinal diseases, designed to provide innovative solutions for end-stage macular degeneration and intraocular drug delivery. The company is currently operating in stealth mode. s
- Sector
- Healthcare
- HQ
- Saint Paul, MN, United States
- Founded
- 2023
- Ownership
- Privately Held (backing)
EyeMacular Regeneration doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EyeMacular Regeneration shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EyeMacular Regeneration in its N-PORT filings yet. We sweep new filings monthly.